Glytec Stock

Glytec is the pioneer of personalized digital therapeutics, enabling best practices for insulin management.

Sign up today and learn more about Glytec Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Glytec Stock

Glytec is the pioneer of personalized digital therapeutics, enabling best practices for inpatient and outpatient insulin management. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for millions who are unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize basal and bolus insulin therapies in the hospital and at home, leading to reductions in hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit

Funding History

July 2009$131K
January 2011$100K
June 2011$2.0M
September 2011$8.3M
November 2012$4.0M
July 2013$3.5M
November 2013$3.0M


VP Quality Initiatives

Raymie McFarland

VP Client Development

Scott Rape

President and CEO

Bob Leonard

Chief Medical Officer

Andrew Rhinehart

VP Clinical Services

Melanie Mabrey

Chief Financial Officer

John Beneke

SVP Research & Development

Robby Booth


drugdeliverybusiness - Jul, 14 2021

Glytec appoints chief medical officer

drugdeliverybusiness - Mar, 31 2021

Glytec launches new insulin management system

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: